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Background:  In South  Africa,  the  ﬁrst  HBV  vaccine  dose  is  administered  at age  6 weeks,  leaving  a  potential
window  for  vertical  transmission.  Insights  into  HBV  seroprevalence  in  the  vulnerable  HIV-infected  group
are important  to  drive  improvements  in surveillance,  treatment  and  prevention.
Objectives:  We  set  out to implement  a screening  program  for HBV  among  HIV-infected  children  and
adolescents  in Kimberley,  South  Africa.  Our  aims  were  to demonstrate  that  screening  is  feasible  and
sustainable,  to establish  the  prevalence  of HBV,  to characterise  the HBV  cases  we  identiﬁed,  and  to  inform
discussion  about  the  infant  vaccination  schedule.
Study design:  We  tested  all HIV positive  children  (age  0–16)  for Hepatitis  B surface  antigen  (HBsAg),
delivering  this  testing  as part  of routine  state-funded  care.  We  followed  up HBsAg-positive  cases  with  an
extended  panel  of HBV  serology  tests,  and  HBV  DNA  viral  load  quantiﬁcation.
Results:  Our  screening  campaign  was  successfully  incorporated  into  routine  out-patient  care.  Among
625 patients  tested,  we found  ﬁve  positive  for HBsAg  (0.8%),  of  whom  three  were  Hepatitis  B  e-antigen
positive.  Two  additional  children  initially  tested  HBsAg-positive  but  were  negative  on repeat  testing.
Antiviral  therapy  in  the  HBsAg  children  was  reviewed  and  adjusted  if  required.
Conclusions:  The  results  testify  to the overall  success  of the  HBV  vaccine  campaign.  However,  we  have
demonstrated  that  ongoing  vigilance  is required  to detect  cases  and  prevent  transmission  events.  Further
evaluation  of the  optimum  timing  of  the  ﬁrst  vaccine  HBV  vaccine  dose  is required;  a vaccine  dose  at
birth  could  reduce  prevalence  further.
© 2016  The  Authors.  Published  by  Elsevier  B.V.  This  is  an open  access  article  under  the  CC  BY  licenseAbbreviations: HBV, hepatitis B virus; WHO, World Health Organisation; EPI,
xpanded programme on immunisation; HIV, human immunodeﬁciency virus;
BsAg, hepatitis B surface antigen; HEU, HIV exposed uninfected; CDC, Centres for
isease Control; MPCI, magnetic parcel chemiluminometric immunoassay; HBeAg,
epatitis B e-antigen; HBeAb, hepatitis B e-antibody; Anti-HBc, IgM hepatitis B anti-
ore IgM antibody; HBsAb, hepatitis B surface antibody; IQR, interquartile range;
otal Anti-HBc, total antibody to hepatitis B core protein; PCR, polymerase chain
eaction; ABC, abacavir; 3TC, lamivudine; rLPV, ritonavir boosted lopinavir; TDF,
enofovir; FTC, emtricitabine; EFV, efavirenz; DTG, dolutegravir.
∗ Corresponding author at: Peter Medawar Building for Pathogen Research, South
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ttp://dx.doi.org/10.1016/j.jcv.2016.10.017
386-6532/© 2016 The Authors. Published by Elsevier B.V. This is an open access article u(http://creativecommons.org/licenses/by/4.0/).
1. Background
Reﬂecting the success of vaccination campaigns, the global
prevalence of chronic Hepatitis B Virus (HBV) infection has fallen
since 1990; however, the absolute number of cases has contin-
ued to rise [1], highlighting the critical need for ongoing efforts
to reduce transmission. The World Health Organisation Expanded
Programme on Immunisation (EPI) recommends that all infants in
settings where HBV prevalence is ≥2% should receive three or four
doses of HBV vaccine, with the ﬁrst dose in the ﬁrst day of life [2].HBV vaccination has been implemented in South Africa since
1995, but the locally recommended schedule is to postpone the
ﬁrst dose until age six weeks [3,4]. Recently, HBV immunisation has
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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een incorporated into a hexavalent vaccine together with diphthe-
ia, tetanus, pertussis, inactivated poliomyelitis and Haemophilus
nﬂuenzae type b (Hexaxim, Sanoﬁ-Pasteur). It is recognized that
hildren with HIV infection may  not mount adequate vaccine-
ediated immunity [5], potentially making this a vulnerable group.
In a recent study to ascertain the epidemiology of HBV in
outh African adults, we identiﬁed HBsAg in 8.3% of HIV-negative,
nd 9.7% of HIV-positive adults [6]. Published around the same
ime, a study from the Western Cape reports 0.4% prevalence of
BV in HIV exposed-uninfected (HEU) infants, all of whom were
BV-immunised according to local policy [4]. Together, these data
ighlight that chronic HBV is a persistent problem in South African
dults, irrespective of HIV status, and that infants remain vulnera-
le to vertical acquisition of HBV infection before receiving their
rst dose of vaccine. In this setting, the high seroprevalence of
IV infection puts infants and young children at increased risk of
o-infection and of complications of chronic HBV infection [4,7].
ur recent study found HBsAg in 11% of HIV-positive mothers of
hildren attending outpatient clinics in Kimberley [6], but HBV-
creening has not been routinely incorporated into clinical care.
. Objectives
We  set out to investigate whether there is evidence of ongoing
BV transmission in our HIV-positive paediatric cohort in Kimber-
ey, South Africa, to ascertain the feasibility of incorporating this
nto routine clinical care, and to characterise the cases of infec-
ion identiﬁed. This study aims to inform ongoing efforts in HBV
creening, treatment and prevention.
. Study design
We  implemented screening for HBsAg in HIV-infected children
age <17 years) attending out-patient clinics at Kimberley Hospi-
al in South African’s Northern Cape, during a ﬁfteen-month period
ommencing March 2015. HBV screening was introduced as part of
outine clinical care in keeping with WHO  and CDC recommenda-
ions [8,9].
Among children who tested HBsAg positive, we  obtained
ritten informed consent for study enrollment from the child
according to age/ability) and their parent/guardian. This study was
pproved under the terms of the Ethics Committee of the Faculty of
ealth Science, University of Free State, Bloemfontein, South Africa
ref. ETOVS Nr 08/09).
We recorded HBV vaccination history for children who attended
ith their hand-held records (Road to Health Book). HBsAg testing
as performed by the clinical laboratory at Kimberley Hospi-
al, using the Magnetic parcel chemiluminometric immunoassay
MPCI; Advia Centaur platform), re-testing samples from an alter-
ative time-point to conﬁrm, where possible. For children testing
BsAg positive, we stored serum at −80 ◦C and shipped samples
o the Oxford University Hospitals microbiology laboratory. We
epeated testing for HBsAg, and additionally performed assays for
BeAg, HBeAb, HBc IgM, HBsAb (all on Architect i2000), and HBV
NA quantiﬁcation (Cobas ampliprep).
. Results
Over a 15-month period, we screened 625 HIV-infected children
nd adolescents for HBV infection (331 male, 294 female; median
ge 10.8 years, IQR 6.6–13.8 years). We  identiﬁed ﬁve (0.8%) who
ere positive for HBsAg (Table 1) including a sibling pair (KHep004
nd KHep005).
A further two children who initially tested HBsAg-positive
KHep001 and KHep003) were negative on repeat testing, and also Virology 85 (2016) 71–74
negative for anti-HBc and for HBV DNA, suggesting that the ini-
tial assay had yielded a false positive result. KHep006 followed
the same initial pattern (initially HBsAg positive, but negative on
follow-up) but had detectable HBV DNA, supporting the presence
of true infection. For KHep007, our conﬁrmation HBsAg test was
done on a sample collected at an earlier timepoint (based on sample
availability). This child tested negative in 2014, but positive in 2016,
suggesting either ﬂuctuations in low level HBsAg, or a new infec-
tion acquired subsequent to 2014. These cases collectively illustrate
the importance of following-up positive screening results with a
conﬁrmation HBsAg test and PCR for HBV DNA.
Only 45 children in this cohort (7%) attended clinic with their
vaccine records (Road to Health Book). Not surprisingly, this group
was signiﬁcantly younger than the rest of the cohort, as par-
ents/guardians of infants and younger children are more likely to
attend with vaccine records (median age of children with records
3.9 years, compared to 11.3 years in those without; p < 0.0001).
Of these 44/45 had received all three HBV vaccine doses, and the
remaining child had received two  doses. One of these 45 was
KHep003, who  initially tested HBsAg positive, but was negative for
HBsAg and HBV DNA on follow-up.
One of the ﬁve children with detectable HBV DNA had a positive
anti-HBs result (KHep006), suggesting prior immunization. This
child seroconverted from HBsAg-positive to HBsAg-negative, and
had only low-level viraemia. We did not identify any child positive
for anti-HBc IgM, suggesting that none of the ﬁve cases was acutely
infected. We detected HBeAg in 3/5 HBsAg-positive children; no
case had detectable anti-HBe (Table 1).
Current South African ART guidelines recommend children are
treated with ABC + 3TC + either rLPV or EFV, but make no speciﬁc
recommendations for therapy in the context of HBV co-infection
[10]. At the time of screening positive for HBsAg, all ﬁve of our HBV-
infected children were on ART regimens incorporating HBV-active
agents (3TC or TDF). In the case of KHep002, the high HBV DNA
level despite 3TC-containing therapy prompted a therapy switch.
Efforts are currently underway to identify and screen household
contacts with the view to treating infection and vaccinating sus-
ceptible individuals.
5. Discussion
This study demonstrates that HBV screening is feasible as part of
routine clinical care for children and adolescents with HIV attend-
ing outpatient clinics in South Africa. We  now propose to continue
this screening as part of routine state-funded care.
Identifying HBV cases allows optimization of antiviral treat-
ment regimens; the case of KHep002 highlights how diagnosing
and monitoring HBV infection can have important bearing on the
choice of ART regimen. The identiﬁcation of an infected sibling pair
in this cohort demonstrates the need for particular vigilance around
the risk of clustering in families, underlining the importance of
preventive measures in tandem with screening.
Both our data-set and another recent study [5] demonstrate the
success of the existing vaccine campaign in reducing paediatric HBV
prevalence. However, there is undoubtedly a need for ongoing vigi-
lance and efforts to reduce transmission still further. Together with
the recent results from the Western Cape [4], these studies sug-
gest that strategies to prevent mother to child HBV transmission
have been successful, but need to remain an important focus. Fur-
thermore, there are ongoing challenges; HBV immunisation is not
routinely available for adults in the public sector (though should be
available for those at risk), and availability of the new hexavalent
vaccine has been problematic.
Routine maternal screening for HBV during pregnancy would
yield beneﬁts for both mother and child, including clinical
P. Jooste et al. / Journal of Clinical Virology 85 (2016) 71–74 73
Table  1
Characteristics of ﬁve HIV-infected children testing positive for HBsAg in Kimberley, South Africa.
Study IDa KHep002 (ART2156) KHep004b
(ART1917)
KHep005b (ART2096) KHep006 (ART1585) KHep007
(ART1638)
Sex F M F M F
Age  (years) at time of
HBV screening
6.8 6.4 15.6 5.6 5.3
Number of doses of
HBV vaccine
3 Unknown Unknown Unknown Unknown
HBsAg test date and
result (MPCIc
Kimberley)
Oct 2015; Detected Apr 2015; Detected Jul 2015;
Detected
Jul 2015;
Detected
Jan 2016;
Detected
Repeat HBsAg test date
and result (MPCIb,
Kimberley)
Nov 2015; Detected Nov 2015; Detected Nov 2015; Detected Feb 2016;
Detected
Not done
Date  of sample used for
conﬁrmation HBsAg
test; result (Architect,
Oxford)
Nov 2015; Detected Jan 2014; Detected Nov 2015; Detected Feb 2016;
Not detected
Sept 2014;
Not detected
Hepatic transaminase
levels (ALT, AST)
Within normal
reference range
Within normal
reference range
Within normal
reference range
Within normal
reference range
Within normal
reference range
Date  and result of most
recent HIV VL (RNA
copies/ml)
Apr 2015;
10,931
Apr 2015; <40 01/08/2013; 196,111 05/01/2014;
25
01/01/2015; <150
Date  and result of most
recent CD4+ T cell
count (CD4%)
Apr 2015;
566 (26%)
Apr 2015;
1500 (38.5%)
Feb 2016;
1883 (40.5%)
Sept 2015;
1135 (31%)
Jan 2015;
2012 (37.3%)
ARTd: start date and
regimen
Jun 2014; ABC/3TC/
EFV
In 2016,
switched to
TDF/FTC/rLPV
Oct 2012; ABC/3TC/EFV Jan 2014; EFV/FTC/TDF Jan 2014
ABC/3TC/rLPV
Mar 2011;
ABC/3TC/rLPV
Since 2014, taking
3TC onlye
HBV DNA (iu/ml) 36,830,065 136,875 110 260 167
HBeAgf Detected Detected Detected Not detected Not detected
Anti-HBeg Not detected Not detected Not detected Not detected Not detected
HBsAbh
(iU/L)
Not detected Not detected Not detected Detected
(212.2)
Not detected
Anti-Hbc IgMi Not detected Not detected Not detected Not detected Not detected
Total  AntiHBcj Not detected Not detected Not detected Not detected Not detected
a Each child testing positive for HBsAg was assigned a new number with the preﬁx K-Hep (Kimberley Hepatitis). In addition, these children each have an ART (Anti-Retroviral
Therapy) study number which we have retained to ensure we can continue to identify these children for clinical follow-up, and in order to permit cross-reference between
studies.
b KHep004 and KHep005 are a sibling pair (same mother; different fathers; mother is deceased).
c MPCI – Magnetic Parcel Chemiluminometric Immunoassay.
d ART – antiretroviral therapy; abbreviations for drugs are as follows: ABC = abacavir; 3TC = lamivudine; rLPV = lopinavir with ritonavir boost (children on rLPV are taking
combination in the form of Kaletra); EFV = efavirenz.
e KHep007 is on 3TC only at present due to difﬁculties with drug adherence, with a plan in place to continue close surveillance and ultimately restart triple therapy,
potentially comprising FTC/TDF/DTG.
f HBeAg – Hepatitis B e-Antigen.
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iAnti-HBe – Antibody to Hepatitis B e-Antigen.
h HBsAb – Hepatitis B surface antibody (vaccine mediated).
i Anti-Hbc IgM – IgM antibody to Hepatitis B core protein.
j Total Anti-HBc – Total antibody to Hepatitis B core protein.
ssessment and appropriate treatment for adult infection, and
mplementation of measures to reduce both vertical and within-
ousehold transmission [11]. Ongoing evaluation of the risks and
eneﬁts of the timing of the ﬁrst HBV vaccine dose is required.
BV immunisation at birth would further reduce perinatal trans-
ission events, and could be given as a monovalent vaccine, with
he hexavalent vaccine following at six weeks to boost antibody
esponses.
The data presented here may  under-represent the true
revalence of HBV infection, by missing cases with low level HBs-
ntigenaemia or in which mutations in HBsAg render the surface
ntigen assay negative [12]. In future studies, screening using HBV
NA as a more sensitive measure could be considered. However,
his is not routinely available and is more expensive, and is there-
ore currently not feasible in South Africa.
We have been unable to make a robust assessment of the spe-
iﬁc details of vaccination history within this cohort, as only 7% of
he cohort had available vaccination records. This small subgroup
annot be deemed representative of the wider population (indeed,
t would be reasonable to hypothesise that families most likely toaccess all three vaccine doses might also be those who are also most
likely to bring their vaccine records to clinic).
Future studies are therefore required to quantify the titres of
vaccine-mediated HBsAb present in this population. Nevertheless,
a prevalence of HBV infection of <1% in children compared to 11% in
the adult population [6] suggests a substantial reduction in trans-
mission, much of which is likely to be attributable to successful
vaccination. While celebrating the impact of campaigns to reduce
HBV infection, we  should maintain a high level of scrutiny to detect
cases and continue intensive efforts to reduce transmission.
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